Holmevis

Holmevis is an intravenous solution containing the active ingredient ibandronate sodium hydrate. It is a prescription bisphosphonate used in the European market for the treatment of osteoporosis. The product is administered by healthcare professionals and is classified under ATC code M05BA07. Holmevis works by targeting bone metabolism to reduce the risk of fractures in patients with low bone density.

Holmevis is indicated for the management of osteoporosis in specific patient groups. It is prescribed to help maintain bone strength and reduce fracture risk.

- Treatment of postmenopausal osteoporosis - Prevention of glucocorticoid‑induced osteoporosis - Long‑term management of established osteoporosis - Adjunct therapy for patients at high risk of vertebral fractures - Use in patients who cannot tolerate oral bisphosphonates

Adverse reactions to Holmevis can vary in frequency and severity.

Common: - Flu-like symptoms (fever, chills, myalgia) - Transient musculoskeletal pain - Nausea or mild gastrointestinal discomfort - Headache - Injection site reactions such as erythema or swelling

Serious: - Acute phase reaction with high fever - Severe renal impairment or acute kidney injury - Hypocalcemia leading to tetany or seizures - Atypical femoral fractures - Osteonecrosis of the jaw

Before initiating Holmevis, certain safety considerations should be reviewed.

- Assess renal function; avoid use in severe renal impairment (creatinine clearance <30 mL/min) - Correct calcium and vitamin D deficiencies prior to treatment - Monitor serum calcium levels during therapy - Use with caution in patients with a history of esophageal disorders - Evaluate for prior or current jaw pathology before administration - Discontinue if acute inflammatory reactions develop after infusion - Discuss pregnancy and lactation status; safety data are limited

Holmevis may interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.

Avoid: - Concomitant use of other bisphosphonates or potent nephrotoxic agents (e.g., aminoglycosides, NSAIDs) - High-dose calcium or magnesium supplements taken within 4 hours of infusion

Use with caution: - Loop diuretics that may affect calcium balance - Antacids containing aluminum or magnesium if administered close to the infusion time - Corticosteroids that increase osteoporosis risk - Vitamin D analogues that may alter calcium homeostasis - Drugs affecting renal function such as ACE inhibitors or ARBs